| Name | Title | Contact Details |
|---|
Furiex Pharmaceuticals, Inc., a drug development company, engages in the compound partnering business primarily in the United States. It collaborates with pharmaceutical and biotechnology companies to enhance the value of their drug candidates by applying its novel approach to drug development. The company’s products under development include Eluxadoline1, a mu opioid receptor agonist and delta opioid receptor antagonist, which is in Phase III clinical trials for the treatment of diarrhea-predominant irritable bowel syndrome; and Avarofloxacin1, a Phase III-ready fluoroquinolone antibiotic for the treatment of acute bacterial skin and skin structure infections. It is also developing SYR-472, which is in Phase III clinical trials for the treatment of Type-2 diabetes. In addition, the company has rights to compounds in various stages of development and commercialization, which includes Nesina, Liovel, Oseni, and Kazano for the treatment of Type-2 diabetes, as well as Priligy for the treatment of premature ejaculation. The company was founded in 1998 and is headquartered in Morrisville, North Carolina.
Heska is dedicated to quality pet care. Through innovation, invention, and strategic partnerships with worldwide leaders in diagnostics and treatments, Heska provides the benefits of latest generation technologies to pet healthcare providers. Heska`s range of complete blood diagnostic solutions include Chemistry, Hematology, Blood Gas & Electrolytes, Immunodiagnostics, Heartworm, and other blood testing. Treatments and testing include Immunotherapy and complete Allergy solutions. Heska`s digital imaging lineup boasts the latest High Definition Digital Radiography and Digital Ultrasound technologies, paired with Cloud Based data archival, management, and sharing services.
Sebra (DBA) is a Tucson, AZ-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Ehave is empowering the mental healthcare community with a next-generation of data-rich tools designed to improve patient management, diagnosis, and treatment. With Ehave Connect, Ehave’s mental health informatics platform, clinicians can make objective, data-driven decisions while keeping patients informed and engaged throughout their mental healthcare journey. Ehave Connect offers a powerful set of core features that integrate with a growing selection of tools and applications developed by Ehave and its leading partners, including Multi-Health Systems (“MHS”), a leading publisher of psychological assessments. Ehave is initially focused on improving the standard of care in attention deficit hyperactivity disorder (“ADHD”), through its collaboration with the Hospital for Sick Children (“SickKids”). Ehave Connect is also being utilized to advance the validation and optimization of medical marijuana, through its collaboration with MedReleaf. Ehave is headquartered in Toronto’s Discovery District, a hub of healthcare, innovation, and technology in Toronto, Canada.
Bolden Instrument is a Hamilton, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.